4,032 reports of this reaction
1.6% of all MYCOPHENOLATE MOFETIL HYDROCHLORIDE reports
#11 most reported adverse reaction
TRANSPLANT REJECTION is the #11 most commonly reported adverse reaction for MYCOPHENOLATE MOFETIL HYDROCHLORIDE, manufactured by Genentech, Inc.. There are 4,032 FDA adverse event reports linking MYCOPHENOLATE MOFETIL HYDROCHLORIDE to TRANSPLANT REJECTION. This represents approximately 1.6% of all 257,534 adverse event reports for this drug.
MYCOPHENOLATE MOFETIL HYDROCHLORIDE has an overall safety score of 92 out of 100. Patients taking MYCOPHENOLATE MOFETIL HYDROCHLORIDE who experience transplant rejection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TRANSPLANT REJECTION is a less commonly reported adverse event for MYCOPHENOLATE MOFETIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to transplant rejection, the following adverse reactions have been reported for MYCOPHENOLATE MOFETIL HYDROCHLORIDE:
The following drugs have also been linked to transplant rejection in FDA adverse event reports:
TRANSPLANT REJECTION has been reported as an adverse event in 4,032 FDA reports for MYCOPHENOLATE MOFETIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TRANSPLANT REJECTION accounts for approximately 1.6% of all adverse event reports for MYCOPHENOLATE MOFETIL HYDROCHLORIDE, making it a notable side effect.
If you experience transplant rejection while taking MYCOPHENOLATE MOFETIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.